Acumen Pharmaceuticals Stock Statistic Functions Beta

ABOS Stock  USD 2.92  -0.17  -5.50%   
The statistic functions view organizes Beta function and supporting indicators around Acumen Pharmaceuticals. It emphasizes statistical functions describing dispersion and variability while keeping volatility, risk, and performance context in view. Enter Time Period to run this model.

This analysis covers thirty-seven data points across the selected time horizon. The Beta measures systematic risk based on how returns on Acumen Pharmaceuticals correlated with the market. If Beta is less than 0 Acumen Pharmaceuticals generally moves in the opposite direction as compared to the market. If Acumen Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Acumen Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Acumen Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Acumen Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.

Acumen Pharmaceuticals Technical Analysis Modules

Technical analysis of Acumen Pharmaceuticals uses historical price and volume data to identify patterns that may signal where the Acumen trend is heading. Pattern recognition signals should be confirmed with momentum or volume data to filter low-conviction setups.

Methodology, Assumptions & Data Sources

Acumen Pharmaceuticals's Statistic Functions history is laid out in the chart below. A strong fit to a straight line suggests the trend is dependable.

This section for Acumen Pharmaceuticals is built from periodic company reporting and market reference feeds, with harmonization applied to align reporting definitions. Analyst projections are included when active coverage applies. Values may update on different source schedules.

This content is curated and reviewed by:

Michael Smolkin - Member of Macroaxis Board of Directors
Last reviewed on March 7th, 2026